drugset / Trial / NCT01530503
Second Line Therapy in Advanced Biliary Tract Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the therapeutic activity of capecitabine alone or in combination with mitomycin C as second-line therapy in patients with advanced/metastatic biliary adenocarcinoma in progression after gemcitabine and platinum compounds
Timeline
- Start
- 2011-11
- Primary completion
- 2013-10
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 2000 mg/m2 | Oral |
| Subject | Mitomycin C | Other / unclassified | 6 mg/m2 | Intravenous |